تداخل‌های دارویی
Nivolumab + Thalidomide
شدت: شدید
Nivolumab and Thalidomide: major interaction.
آخرین به‌روزرسانی
ویژه کادر درمان — فقط جهت مرجع. این صفحه خلاصه‌ای کوتاه است، توصیه پزشکی نیست و جایگزین بروشور رسمی یا قضاوت بالینی نمی‌شود. پیش از تجویز یا تحویل دارو همیشه بررسی کنید.
محتوای بالینی این صفحه فقط به زبان انگلیسی موجود است.
خلاصه
Thalidomide is an immunomodulator, and concurrent use with PD-1 antibodies in multiple myeloma has been linked to excess mortality in trials of pembrolizumab combinations. Nivolumab is expected to share this class risk, though direct evidence is limited. Outside a clinical trial the combination offers no proven benefit.
معنای این تداخل به زبان ساده
Nivolumab and Thalidomide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Nivolumab belongs to Oncology; Thalidomide belongs to Miscellaneous.
چرا رخ می‌دهد
Combined immune modulation with PD-1 blockade and thalidomide analogs; the mechanism of excess harm is not fully established.
اقدام لازم
Avoid combining nivolumab with thalidomide or related agents in multiple myeloma outside a clinical trial. If used, monitor closely for immune-related adverse events and infections.
از داروساز چه بپرسید
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
ویژه اعضای Pro+
باز کردن کل صفحه
یک حساب بسازید و دوره آزمایشی Pro+ را شروع کنید تا توصیه‌های کامل مدیریت Nivolumab و Thalidomide، یادداشت‌های تکمیلی، جزئیات شواهد و بررسی‌کننده تداخل برای کل نسخه را باز کنید.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Pro+ را ۷ روز رایگان در وب امتحان کنید. بدون نیاز به کارت.
تداخلات دیگر Nivolumab
تداخلات دیگر Thalidomide
پرسش‌های متداول
Can I take Nivolumab with Thalidomide?
MediHelp rates the interaction as major. Nivolumab and Thalidomide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Thalidomide is an immunomodulator, and concurrent use with PD-1 antibodies in multiple myeloma has been linked to excess mortality in trials of pembrolizumab combinations. Nivolumab is expected to share this class risk, though direct evidence is limited. Outside a clinical trial the combination offers no proven benefit.
How serious is the interaction between Nivolumab and Thalidomide?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combining nivolumab with thalidomide or related agents in multiple myeloma outside a clinical trial. If used, monitor closely for immune-related adverse events and infections.
What other medicines interact with Nivolumab?
MediHelp also lists interactions of Nivolumab with, for example, Dexamethasone-tobramycin, Dexamethasone, Efgartigimod / hyaluronidase sc. The full list is on the Nivolumab page.
تک‌نگاری کامل، دوزاژ و بررسی تداخل دارویی در برنامه MediHelp
مرجع کامل را باز کنید، تداخل چند دارو را بررسی کنید و از ابزارهای دوز در برنامه MediHelp استفاده کنید.
